Clinical-stage biotechnology company SparX Biopharmaceutical Corp announced on Thursday that it has entered into a research agreement with Mitsubishi Tanabe Pharma America Inc (MTPA).

The collaboration aims to advance an antibody-drug conjugate (ADC) programme focused on a conceptually novel immune cell target-based ADC.

The research will focus on an ADC against a first-in-class immune cell target, with the potential to serve as a universal tumour-targeting strategy across multiple cancer types.

"This collaboration marks significant milestone for SparX, reflecting the strength of our novel target discovery capabilities," said Gui-Dong Zhu, Ph.D., founder and CEO of SparX Biopharmaceutical Corp. "We are excited to work alongside MTPA to bring transformative ADC therapies to patients worldwide."